Paul Schnitzler - Infectious Diseases

Author Information

Paul Schnitzler is affiliated with the Department of Infectious Diseases, Virology, at the University of Heidelberg, located in Heidelberg, Germany. His research primarily focuses on infectious diseases, with a significant contribution to understanding viral infections and the development of diagnostic tests.

Research Contributions

Paul Schnitzler has made substantial contributions to the field of infectious diseases, particularly in the study of viral infections such as SARS-CoV-2 and Hepatitis C. His work includes evaluating the accuracy and effectiveness of diagnostic tests and vaccines. In recent studies, he has focused on the effectiveness of COVID-19 vaccines against emerging variants and the immune response in specific patient groups, such as those with underlying health conditions or post-transplant patients.

Aliases

Paul Schnitzler is also known by the aliases P Schnitzler and P. Schnitzler.

Publication and Citation Metrics

Citation Count	8768
h-index	49
Paper Count	288

Publications:

A Multi-Center Clinical Diagnostic Accuracy Study of Surestatus - an Affordable, WHO Emergency-Use-Listed, Rapid, Point-of-Care, Antigen-Detecting Diagnostic Test for SARS-CoV-2

DOI: 10.2139/ssrn.4072491

Year: 2022

Molecular epidemiology of respiratory syncytial virus in hospitalised children in Heidelberg, Southern Germany, 2014-2017.

DOI: 10.1016/j.meegid.2022.105209

Year: 2022

Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers

DOI: 10.1016/j.cmi.2022.01.011

Year: 2022

Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis

DOI: 10.1097/HS9.0000000000000688

Year: 2022

Accuracy and ease-of-use of seven point-of-care SARS-CoV-2 antigen-detecting tests: A multi-centre clinical evaluation

DOI: 10.1016/j.ebiom.2021.103774

Year: 2022

A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo

DOI: 10.1101/2022.03.28.486019

Year: 2022

SARS-CoV-2 Variant of Concern B.1.1.7: Diagnostic Sensitivity of Three Antigen-Detecting Rapid Tests

DOI: 10.1128/spectrum.00763-21

Year: 2022

Impaired Neutralizing Antibody Activity against B.1.617.2 (Delta) after Anti-SARS-CoV-2 Vaccination in Patients Receiving Anti-CD20 Therapy

DOI: 10.3390/jcm11061739

Year: 2022

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variant after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.

DOI: 10.1111/ajt.17054

Year: 2022

Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis

DOI: 10.1136/annrheumdis-2021-221747

Year: 2022

What is Pathogenesis?

Is There a Vaccine for Yellow Fever?

How are Structural Proteins Targeted in Vaccine Development?

What is the Warburg Effect?

How Does Chronic Inflammation Affect Infectious Diseases?

Can Flaviviridae infections be prevented?

How Can HPV Infection be Prevented?

What are the Symptoms of Dengue Hemorrhagic Fever?

What are the controversies surrounding Dengvaxia?

How is Lyme Disease Diagnosed?

Partnered Content Networks

Relevant Topics